(8 days)
No
The summary describes a mechanical extracorporeal support system and does not mention any AI or ML components or capabilities.
Yes
The device is used for "extracorporeal gas exchange support and blood temperature control" during surgical procedures, which are therapeutic interventions.
No
Explanation: The device, Ideal Mimesys, is described as an "extracorporeal hemodynamic and gas exchange support system" used in "surgical procedures requiring extracorporeal gas exchange support and blood temperature control." Its components include an oxygenator, heat exchanger, arterial filter, and centrifugal pump. These functions are therapeutic and supportive of physiological functions, not diagnostic.
No
The device description explicitly lists multiple hardware components including a membrane oxygenator, heat exchanger, arterial filter, venous air removal device, centrifugal pump, and pump bracket.
Based on the provided text, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use clearly states the device is for "adult surgical procedures requiring extracorporeal gas exchange support and blood temperature control." This describes a device used on a patient during surgery, not a device used to test samples from a patient outside the body.
- Device Description: The description details components like a membrane oxygenator, heat exchanger, arterial filter, and centrifugal blood pump. These are all components of an extracorporeal circuit used to support a patient's physiological functions during surgery.
- Lack of IVD Characteristics: There is no mention of analyzing biological samples (blood, urine, tissue, etc.) to provide diagnostic information. The device's function is to directly interact with and modify the patient's blood flow and gas exchange.
Therefore, the Ideal Mimesys system is an extracorporeal life support device, not an in vitro diagnostic device.
N/A
Intended Use / Indications for Use
Ideal Mimesys is intended to be used in adult surgical procedures requiring extracorporeal gas exchange support and blood temperature control. Ideal Mimesys must not be used longer than 6 hours. Contact with blood for longer periods is inadvisable. Ideal Mimesys is intended for use with the Stöckert Centrifugal Pump Console.
Product codes (comma separated list FDA assigned to the subject device)
74 KFM
Device Description
IDEAL MIMESYS System with Integrated Venous Air Removal, Centrifugal Blood Pump, Pump Bracket, Adult Membrane Oxygenator, Heat Exchanger and Arterial Filter Mimesys Treated (PhosphoryIcholine coating hereinafter called PC coating) is an extracorporeal hemodynamic and gas exchange support system for extracorporeal perfusion. IDEAL MIMESYS consists of a high efficiency, microporous, hollow fiber membrane oxygenator integrated with a heat exchanger and an arterial filter (Synthesis Mimesys Adult Membrane Oxygenator, K031223) connected to an active venous air removal device (defoamer), a centrifugal pump (Cobe Revolution Centrifugal Blood Pump with PC coating, K030462) and a pump bracket.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
adult
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
IN VITRO TEST RESULTS:
In vitro testing were carried out in accordance with the requirements of "Guidance for Cardiopulmonary Bypass Oxygenators 510(k) submissions - Final Guidance for Industry and FDA Staff" issued on November 13, 2000 - "Guidance for Blood Extracorporeal Blood Circuit Defoamer 510(k) Submission" Final Guidance for Industry and FDA issued on November 29, 2000 - "Guidance for Cardiopulmonary Bypass Arterial line Blood Filter 510(k) Submission" Final Guidance for industry and FDA issued on November 29, 2000 and the ISO 7199 (1996) standard for "Cardiovascular Implants and Artificial Organs - Extra Corporeal Blood-Gas Exchangers (Oxygenator)" when applicable for providing the data necessary to demonstrate both substantial equivalence with the predicate device and also compliance with safety and effectiveness requirements. The device was aged up to 3 years and was tested for mechanical integrity, connection testing, pressure drop and microembolic activity of the venous bubble trap, hemolysis/cell depletion, uniformity test and flaking/leaching of the PC coating. The results of these tests met established specifications. For comparative purposes, the same testing, when applicable, has been conducted also on the IDEAL predicate device. Considering the modification of the current submission involves the extension of the integrated arterial filter and the IDEAL MIMESYS utilizes the same integrated arterial filter as the SYNTHESIS MIMESYS predicate device, this 510(k) cross references performance data previously submitted in the SYNTHESIS MIMESYS 510(k) (K031223) for the phosphoryicholine coated arterial filter characterization. Furthermore, the extension of the PC coating also affects the centrifugal pump. The IDEAL MIMESYS utilizes the same integrated centrifugal pump as the REVOLUTION PUMP PC COATED predicate device, this 510(k) cross references performance data previously submitted in the REVOLUTION PUMP PC COATED 510(k) (K030462). The oxygenating module with integrated heat exchanger is not affected by the modification. This 510(k) cross references performance data previously submitted in the SYNTHESIS 510(k) (K022450) for the gas transfer studies, oxygenating module pressure drop evaluation, heat exchanger performance evaluation and blood compatibility characterization.
The results of the study showed the device characteristics between IDEAL MIMESYS and IDEAL. were comparable.
CONCLUSIONS:
The results of in vitro studies demonstrate that the IDEAL MIMESYS devices perform in a manner substantially equivalent to the predicate device. Biocompatibility studies demonstrate that the phosphorylcholine coating is biocompatible and functional tests demonstrate that Ideal Mimesvs performance are equivalent to the IDEAL predicate device, according to its intended use. Additional testing has demonstrated the effectiveness of production techniques to assure that the oxygenator is sterile and non-pyrogenic.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
K030154, K031223, K022450, K030462
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 870.4360 Nonroller-type blood pump.
(a)
Nonroller-type cardiopulmonary and circulatory bypass blood pump —(1)Identification. A nonroller-type cardiopulmonary and circulatory bypass blood pump is a prescription device that uses a method other than revolving rollers to pump the blood through an extracorporeal circuit for periods lasting less than 6 hours for the purpose of providing either:(i) Full or partial cardiopulmonary bypass (
i.e., circuit includes an oxygenator) during open surgical procedures on the heart or great vessels; or(ii) Temporary circulatory bypass for diversion of flow around a planned disruption of the circulatory pathway necessary for open surgical procedures on the aorta or vena cava.
(2)
Classification —Class II (special controls). The special controls for this device are:(i) Non-clinical performance testing must perform as intended over the intended duration of use and demonstrate the following: Operating parameters, dynamic blood damage, heat generation, air entrapment, mechanical integrity, and durability/reliability;
(ii) The patient-contacting components of the device must be demonstrated to be biocompatible;
(iii) Sterility and shelf life testing must demonstrate the sterility of patient-contacting components and the shelf life of these components; and
(iv) Labeling must include information regarding the duration of use, and a detailed summary of the device- and procedure-related complications pertinent to use of the device.
(b)
Nonroller-type temporary ventricular support blood pump —(1)Identification. A nonroller-type temporary ventricular support blood pump is a prescription device that uses any method resulting in blood propulsion to provide the temporary ventricular assistance required for support of the systemic and/or pulmonary circulations during periods when there is ongoing or anticipated hemodynamic instability due to immediately reversible alterations in ventricular myocardial function resulting from mechanical or physiologic causes. Duration of use would be less than 6 hours.(2)
Classification. Class III (premarket approval).(c)
Date premarket approval application (PMA) or notice of completion of product development protocol (PDP) is required. A PMA or notice of completion of a PDP is required to be filed with FDA on or before September 8, 2015, for any nonroller-type temporary ventricular support blood pump that was in commercial distribution before May 28, 1976, or that has, on or before September 8, 2015, been found to be substantially equivalent to any nonroller-type temporary ventricular support blood pump that was in commercial distribution before May 28, 1976. Any other nonroller-type temporary ventricular support blood pump shall have an approved PMA or declared completed PDP in effect before being placed in commercial distribution.
0
037040 ji_
| 510(k) SUMMARY | |
|---|---|
| SUBMITTER: | Dideco S.p.A. |
| 86, Via Statale 12 Nord | |
| 41037 Mirandola (MO) Italy | |
| CONTACT PERSON: | Luigi Vecchi |
| Phone: 011 39 0535 29811 | |
| Fax: 011 39 0535 25229 | |
| DATE PREPARED: | June 30, 2003 |
| DEVICE TRADE NAME: | IDEAL MIMESYS System with Integrated Venous |
| Air Removal, Centrifugal Blood Pump, Pump Bracket, Adult Membrane Oxygenator, Heat | |
| Exchanger and Arterial Filter Mimesys Treated | |
| (Phosphorylcholine coating hereinafter called PC coating) | |
| COMMON NAME: | Hollow Fiber Membrane Oxygenator with |
| Integrated Arterial Filter and Heat Exchanger, | |
| Venous Defoamer, | |
| Centrifugal Blood Pump | |
| CLASSIFICATION NAME: | Cardiopulmonary Bypass Oxygenator/ |
| Cardiopulmonary Bypass Heat Exchanger/ | |
| Cardiopulmonary Bypass Arterial Line Blood | |
| Filter / Cardiopulmonary Bypass Defoamer/ Non- | |
| Roller Type Cardiopulmonary Blood Pump | |
| PREDICATE DEVICES: | IDEAL System with Integrated Venous Air |
| Removal, Centrifugal Blood Pump, Pump Bracket, Adult Membrane Oxygenator, Heat | |
| Exchanger and Arterial Filter (K030154) |
SYNTHESIS MIMESYS Adult Membrane
Oxygenator with Integrated Arterial Filter and
Hardshell Venous/Cardiotomy Reservoir
Mimesys Treated (K031223)
SYNTHESIS Adult Membrane Oxygenator with
Integrated Arterial Filter and Hardshell
Venous/Cardiotomy Reservoir Mimesys Treated
(K022450)
Cobe Cardiovascular REVOLUTION
CENTRIFUGAL BLOOD PUMP with PC coating
(K030462) |
1
DEVICE DESCRIPTION:
IDEAL MIMESYS System with Integrated Venous Air Removal, Centrifugal Blood Pump, Pump Bracket, Adult Membrane Oxygenator, Heat Exchanger and Arterial Filter Mimesys Treated (PhosphoryIcholine coating hereinafter called PC coating) is an extracorporeal hemodynamic and gas exchange support system for extracorporeal perfusion. IDEAL MIMESYS consists of a high efficiency, microporous, hollow fiber membrane oxygenator integrated with a heat exchanger and an arterial filter (Synthesis Mimesys Adult Membrane Oxygenator, K031223) connected to an active venous air removal device (defoamer), a centrifugal pump (Cobe Revolution Centrifugal Blood Pump with PC coating, K030462) and a pump bracket.
INDICATION FOR USE:
IDEAL MIMESYS is a sterile, nonpyrogenic device intended to be used in adult surgical procedures requiring extracorporeal gas exchange support and blood temperature control. IDEAL MIMESYS must not be used longer than 6 hours. Contact with blood for longer periods is inadvisable. Ideal Mimesys is intended for use only with the Stöckert Centrifugal Pump Console.
TECHNOLOGICAL CHARACTERISTICS:
The IDEAL MIMESYS System with Integrated Venous Air Removal, Centrifugal Blood Pump, Pump Bracket, Adult Membrane Oxygenator, Heat Exchanger and Arterial Filter Mimesys Treated (Phosphorylcholine coating hereinafter called PC coating), is identical to the IDEAL predicate device with respect to operating principles, control mechanisms and biocompatibility of the PC coating. The only modification made to the IDEAL MIMESYS is the extension of the coating. already present on the oxyqenating module, to all blood contact surfaces including the integrated arterial filter, the centrifugal pump, the venous air removal device and connections. The coating is identical to the phosphorycholine coating used on IDEAL, SYNTHESIS, SYNTHESIS MIMESYS and REVOLUTION CENTRIFUGAL BLOOD PUMP with PC coating predicate devices.
The oxygenator is ethylene oxide sterilized and has a nonpyrogenic fluid path. It is for single use only.
BIOCOMPATIBILITY TEST RESULTS:
A complete battery of tests were carried out in accordance with the requirements of ISO 10993-1:1995 and the FDA May 1. 1995 Memorandum on the use of the ISO 10993 standard for biocompatibility testing on the raw materials. Testing was performed on the SYNTHESIS (accelerated aging). The device, aged up to three years, was tested for Hemolysis, Cytotoxicity, Irritation, Acute Systemic Toxicity and Mutagenicity. Sterility, Pyrogenicity, ETO residuals, and package integrity testing were also conducted. The results of the testing met established specifications.
2
IN VITRO TEST RESULTS:
In vitro testing were carried out in accordance with the requirements of "Guidance for Cardiopulmonary Bypass Oxygenators 510(k) submissions - Final Guidance for Industry and FDA Staff" issued on November 13, 2000 - "Guidance for Blood Extracorporeal Blood Circuit Defoamer 510(k) Submission" Final Guidance for Industry and FDA issued on November 29, 2000 - "Guidance for Cardiopulmonary Bypass Arterial line Blood Filter 510(k) Submission" Final Guidance for industry and FDA issued on November 29, 2000 and the ISO 7199 (1996) standard for "Cardiovascular Implants and Artificial Organs - Extra Corporeal Blood-Gas Exchangers (Oxygenator)" when applicable for providing the data necessary to demonstrate both substantial equivalence with the predicate device and also compliance with safety and effectiveness requirements. The device was aged up to 3 years and was tested for mechanical integrity, connection testing, pressure drop and microembolic activity of the venous bubble trap, hemolysis/cell depletion, uniformity test and flaking/leaching of the PC coating. The results of these tests met established specifications. For comparative purposes, the same testing, when applicable, has been conducted also on the IDEAL predicate device. Considering the modification of the current submission involves the extension of the integrated arterial filter and the IDEAL MIMESYS utilizes the same integrated arterial filter as the SYNTHESIS MIMESYS predicate device, this 510(k) cross references performance data previously submitted in the SYNTHESIS MIMESYS 510(k) (K031223) for the phosphoryicholine coated arterial filter characterization. Furthermore, the extension of the PC coating also affects the centrifugal pump. The IDEAL MIMESYS utilizes the same integrated centrifugal pump as the REVOLUTION PUMP PC COATED predicate device, this 510(k) cross references performance data previously submitted in the REVOLUTION PUMP PC COATED 510(k) (K030462). The oxygenating module with integrated heat exchanger is not affected by the modification. This 510(k) cross references performance data previously submitted in the SYNTHESIS 510(k) (K022450) for the gas transfer studies, oxygenating module pressure drop evaluation, heat exchanger performance evaluation and blood compatibility characterization.
The results of the study showed the device characteristics between IDEAL MIMESYS and IDEAL. were comparable.
CONCLUSIONS:
The results of in vitro studies demonstrate that the IDEAL MIMESYS devices perform in a manner substantially equivalent to the predicate device. Biocompatibility studies demonstrate that the phosphorylcholine coating is biocompatible and functional tests demonstrate that Ideal Mimesvs performance are equivalent to the IDEAL predicate device, according to its intended use. Additional testing has demonstrated the effectiveness of production techniques to assure that the oxygenator is sterile and non-pyrogenic.
3
Image /page/3/Picture/1 description: The image is a black and white logo for the Department of Health & Human Services - USA. The logo is circular in shape, with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter of the circle. In the center of the circle is a stylized image of an eagle.
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
ിന്നും 9 2003
Dideco S.P.A. c/o Mr. Barry Sall Parexel International Corp. 195 West Street Waltham, MA 02451-1163
Re: K032040
Ideal Mimesys System with Integrated Venous Air Removal Regulation Number: 870.4360 Regulation Name: Non-Roller Type CPB Blood Pump Regulatory Class: Class III (three) Product Code: 74 KFM Dated: June 30, 2003 Received: July 1, 2003
Dear Mr. Sall:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
4
Page 2 - Mr. Barry Sall
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4646. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html
Sincerely yours,
Qale TM
Bram D. Zuckerman, M.D.
Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
5
Image /page/5/Picture/0 description: The image shows the word "dideco" in a stylized, bold, sans-serif font. The letters are closely spaced and connected, giving the word a unified appearance. The entire word is rendered in black against a white background, creating a high-contrast visual.
DIDECO S.p.A.
510(k) Number (if known): ____________________________________________________________________________________________________________________________________________________
Device Name: IDEAL MIMESYS System with Integrated Venous Air Removal, Centrifugal Blood Pump Pump Holder, Adult Membrane Oxygenator, Heat Exchanger and Arterial Filter Mimesys Treated
Indications For Use:
Ideal Mimesys is intended to be used in adult surgical procedures requiring extracorporeal gas exchange support and blood temperature control. Ideal Mimesys must not be used longer than 6 hours. Contact with blood for longer periods is inadvisable. Ideal Mimesys is intended for use with the Stöckert Centrifugal Pump Console.
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NECESSARY)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use
(Per 21 CFR 801.109)
OR Over-The-Counter Use
Quettn
510(k) Number K032040